Predicting Cycle One Serious Drug-Related Toxicity (SDRT) in Phase I Oncology Trial

Purpose: To identify a patient undergoing a Phase I oncology trial at risk for a serious drug-related toxicity (SDRT) based on the study of Hyman et al.

Info MyLikes MyPaths

Evaluation

Are you evaluating a patient undergoing a Phase I oncology clinical trial?

Yes

Serum albumin

Serum AST

U/L

WBC count

Creatinine clearance

mL/min

Number of agents being used

Is a biological agent being used?

Yes

ECOG performance status

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Total score

Probability of a serous drug-related toxicity (SDRT) due to therapy

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
Criteria For Diagnosis
- Advanced Stage Hodgkin Disease | Score for Treatment-Related Mortality (TRM)
Severity, Prognosis, Stage
- Tool for Predicting Acute Chemotherapy-Induced Nausea and Vomiting (CINV)
- Advanced Stage Hodgkin Disease | Score for Treatment-Related Mortality (TRM)
Complications

Therapy

Selection
- Anticipatory Nausea Index for Cancer Chemotherapy
Prevention
- Emetic Effect of Chemotherapeutic Agents

Monitoring

Response To Therapy
Adverse Effects

Specialty

Hematology Oncology

Objective

dosage calculations
adverse effects
drug levels
overdose and reversal

ICD-10

T45.1 - Poisoning, antineoplastic and immunosuppressive drugs
Y43.3 - Adverse effects in therapeutic use, other antineoplastic drugs

Info

Purpose: To identify a patient undergoing a Phase I oncology trial at risk for a serious drug-related toxicity (SDRT) based on the study of Hyman et al.

Specialty: Hematology Oncology

Objective: dosage calculations, adverse effects, drug levels, overdose and reversal

ICD-10: T45.1, Y43.3,

Save Data

Identifier

Enter 1 to 5 characters as ID

Email

Your registered email

Other

Email to

Please separate multiple email IDs with comma (,)

Consult Report

Identifier

Enter 1 to 5 characters as ID

Add to MyPath

Select path

New path